I know @Davisite says we're more advanced than what some media states, but having a look at the full program, I believe clarity is still earlier than its peers.
255ac is in the main prostate cancer speaking program, whilst clarity is speaking in a program where they're still discussing the viability of cu64/67.
I believe this shows why moves were made for other radioconjugates, and we're still moving forward. I hope this stays the case until we at least release our P1/2 data. P1 255ac has been out for years, whereas clarity hasn't formally released and Journal articles about their cu67, as it's still in progress.
I know @Davisite says we're more advanced than what some media...
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.95 |
Change
0.150(5.36%) |
Mkt cap ! $919.9M | |||
| Open | High | Low | Value | Volume |
| $2.77 | $2.99 | $2.76 | $1.886M | 648.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 4847 | $2.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.97 | 3282 | 4 |
View Market Depth
| Last trade - 11.34am 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.95 |
Change
0.150 ( 5.50 %) |
||||
| Open | High | Low | Volume | ||
| $2.79 | $2.99 | $2.79 | 50548 | ||
| Last updated 11.48am 01/05/2024 ? | |||||
| CU6 (ASX) Chart |